Advances in preclinical investigation of prostate cancer gene therapy

Marxa L. Figueiredo, Chinghai Kao, Lily Wu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Treating recurrent prostate cancer poses a great challenge to clinicians. Research efforts in the last decade have shown that adenoviral vector-based gene therapy is a promising approach that could expand the arsenal against prostate cancer. This maturing field is at the stage of being able to translate many preclinical discoveries into clinical practices. At this juncture, it is important to highlight the promising strategies including prostate-targeted gene expression, the use of oncolytic vectors, therapy coupled to reporter gene imaging, and combined treatment modalities. In fact, the early stages of clinical investigation employing combined, multimodal gene therapy focused on loco-regional tumor eradication and showed promising results. Clinicians and scientists should seize the momentum of progress to push forward to improve the therapeutic outcome for the patients.

Original languageEnglish (US)
Pages (from-to)1053-1064
Number of pages12
JournalMolecular Therapy
Volume15
Issue number6
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Neoplasm Genes
Genetic Therapy
Prostatic Neoplasms
Reporter Genes
Prostate
Therapeutics
Gene Expression
Research
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Advances in preclinical investigation of prostate cancer gene therapy. / Figueiredo, Marxa L.; Kao, Chinghai; Wu, Lily.

In: Molecular Therapy, Vol. 15, No. 6, 06.2007, p. 1053-1064.

Research output: Contribution to journalArticle

Figueiredo, Marxa L. ; Kao, Chinghai ; Wu, Lily. / Advances in preclinical investigation of prostate cancer gene therapy. In: Molecular Therapy. 2007 ; Vol. 15, No. 6. pp. 1053-1064.
@article{f7226601f0ce4678a5c373c5c5d58c0e,
title = "Advances in preclinical investigation of prostate cancer gene therapy",
abstract = "Treating recurrent prostate cancer poses a great challenge to clinicians. Research efforts in the last decade have shown that adenoviral vector-based gene therapy is a promising approach that could expand the arsenal against prostate cancer. This maturing field is at the stage of being able to translate many preclinical discoveries into clinical practices. At this juncture, it is important to highlight the promising strategies including prostate-targeted gene expression, the use of oncolytic vectors, therapy coupled to reporter gene imaging, and combined treatment modalities. In fact, the early stages of clinical investigation employing combined, multimodal gene therapy focused on loco-regional tumor eradication and showed promising results. Clinicians and scientists should seize the momentum of progress to push forward to improve the therapeutic outcome for the patients.",
author = "Figueiredo, {Marxa L.} and Chinghai Kao and Lily Wu",
year = "2007",
month = "6",
doi = "10.1038/sj.mt.6300181",
language = "English (US)",
volume = "15",
pages = "1053--1064",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Advances in preclinical investigation of prostate cancer gene therapy

AU - Figueiredo, Marxa L.

AU - Kao, Chinghai

AU - Wu, Lily

PY - 2007/6

Y1 - 2007/6

N2 - Treating recurrent prostate cancer poses a great challenge to clinicians. Research efforts in the last decade have shown that adenoviral vector-based gene therapy is a promising approach that could expand the arsenal against prostate cancer. This maturing field is at the stage of being able to translate many preclinical discoveries into clinical practices. At this juncture, it is important to highlight the promising strategies including prostate-targeted gene expression, the use of oncolytic vectors, therapy coupled to reporter gene imaging, and combined treatment modalities. In fact, the early stages of clinical investigation employing combined, multimodal gene therapy focused on loco-regional tumor eradication and showed promising results. Clinicians and scientists should seize the momentum of progress to push forward to improve the therapeutic outcome for the patients.

AB - Treating recurrent prostate cancer poses a great challenge to clinicians. Research efforts in the last decade have shown that adenoviral vector-based gene therapy is a promising approach that could expand the arsenal against prostate cancer. This maturing field is at the stage of being able to translate many preclinical discoveries into clinical practices. At this juncture, it is important to highlight the promising strategies including prostate-targeted gene expression, the use of oncolytic vectors, therapy coupled to reporter gene imaging, and combined treatment modalities. In fact, the early stages of clinical investigation employing combined, multimodal gene therapy focused on loco-regional tumor eradication and showed promising results. Clinicians and scientists should seize the momentum of progress to push forward to improve the therapeutic outcome for the patients.

UR - http://www.scopus.com/inward/record.url?scp=34249315474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249315474&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300181

DO - 10.1038/sj.mt.6300181

M3 - Article

C2 - 17457317

AN - SCOPUS:34249315474

VL - 15

SP - 1053

EP - 1064

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -